指南与共识乳腺PETCT

乳腺浸润性导管癌分子亚型与FDG PET/CT葡萄糖代谢的相关性:基于2013年圣加仑共识会议推荐

Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013.
指南 / 共识 · Nucl Med Mol Imaging · 2016-08-15

回顾183例乳腺浸润性导管癌初诊分期患者,按2013年圣加仑共识分型,比较原发灶SUVmax与分子亚型的关系。各亚型SUVmax差异有统计学意义(p<0.001)但重叠宽,LA与非LA鉴别最佳阈值5.9,敏感度79.4%、特异度57.9%、AUC 0.704。

要点

  • 三阴性及HER2阳性型SUVmax均值最高,LA型最低,但各亚型间SUVmax重叠宽。
  • LA与非LA鉴别阈值SUVmax 5.9,敏感度79.4%、特异度57.9%、AUC 0.704。
  • SUVmax可用于辅助免疫组化区分分子亚型,但单独用于个体患者受限。

核心结论

  • SUVmax与分子亚型显著相关,可辅助免疫组化区分亚型,但因SUVmax重叠宽,用于个体患者可能受限。

研究设计与样本

  • 回顾性分析183例因乳腺浸润性导管癌初诊分期行F-18 FDG PET/CT患者的临床记录,按2013年圣加仑共识会议推荐定义分子亚型并与临床组织病理特征相关分析。

关键影像表现/征象

  • LA组38例、LBHER2-组72例、LBHER2+组21例、HER2+组30例、TN组22例。
  • LA、LBHER2-、LBHER2+、HER2+、TN组SUVmax均值分别为4.5±2.3、7.2±4.9、7.2±4.3、10.2±5.5、8.8±7.1。
  • 各亚型间SUVmax差异有统计学意义(p<0.001),但数值重叠宽。

诊断标准与关键数值

  • LA与LBHER2-鉴别最佳SUVmax阈值5.9,AUC 0.648。
  • LA与LBHER2+鉴别最佳SUVmax阈值5.8,AUC 0.709。
  • LA与HER2+鉴别最佳SUVmax阈值7.5,AUC 0.833。
  • LA与TN鉴别最佳SUVmax阈值10.2,AUC 0.697。
  • LA与非LA鉴别阈值SUVmax 5.9,敏感度79.4%、特异度57.9%、AUC 0.704。

临床应用与阅片要点

  • 阅片时可结合SUVmax与免疫组化结果辅助判断分子亚型,但需注意各亚型SUVmax重叠宽,不宜单独据此分型。

局限性

  • 原文指出各亚型SUVmax数值重叠宽,SUVmax测量用于个体患者区分分子亚型可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to investigate the relationship between the SUVmax of primary breast cancer lesions and the molecular subtypes based on the recommendations of the St. Gallen consensus meeting 2013.

METHODS: Clinical records of patients who underwent F-18 FDG PET/CT for initial staging of invasive ductal carcinoma (IDC) of the breast were reviewed. A total of 183 patients were included. SUVmax was correlated with the molecular subtypes defined by the St. Gallen Consensus Meeting 2013, i.e., luminal A-like (LA), luminal B-like HER2 negative (LBHER2-), luminal B-like HER2 positive (LBHER2+), HER2 positive (HER2+), and triple negative (TN), and with the clinicohistopathologic characteristics.

RESULTS: The molecular subtype was LA in 38 patients, LBHER2- in 72, LBHER2+ in 21, HER2+ in 30, and TN in 22. The mean SUVmax in the LA, LBHER2-, LBHER2+, HER2+, and TN groups were 4.5 ± 2.3, 7.2 ± 4.9, 7.2 ± 4.3, 10.2 ± 5.5, and 8.8 ± 7.1, respectively. Although SUVmax differed significantly among these subtypes (p < 0.001), the values showed a wide overlap. Optimal cut-off SUVmax to differentiate LA from LBHER2-, LBHER2+, HER2+ and TN were 5.9, 5.8, 7.5, and 10.2 respectively, with area under curve (AUC) of 0.648, 0.709, 0.833, and 0.697 respectively. The cut-off value of 5.9 yielded the highest accuracy for differentiation between the LA and non-LA subtypes, with sensitivity, specificity, and AUC of 79.4 %, 57.9 %, and 0.704 respectively.

CONCLUSION: The SUVmax showed a significant correlation with the molecular subtype. Although SUVmax measurements could be used along with immunohistochemical analysis for differentiating between molecular subtypes, its application to individual patients may be limited due to the wide overlaps in SUVmax.

来源:Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lee SS, Bae SK, Park YS, et al. Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013. Nucl Med Mol Imaging. 2016. PMID: 28250861. doi:10.1007/s13139-016-0444-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。